⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL27585236 | 0.85 | DAO (0.53) | — | |
| SCHEMBL14854150 | 0.82 | CES2 (0.75) | — | |
| SCHEMBL6181512 | 0.82 | F2 (0.71) | — | |
| SCHEMBL1244072 | 0.80 | CES2 (0.73) | — | |
| SCHEMBL5957241 | 0.78 | — | — | |
| SCHEMBL71972 | 0.78 | — | — | |
| SCHEMBL1455897 | 0.76 | — | — | |
| SCHEMBL27417909 | 0.76 | — | — | |
| SCHEMBL345568 | 0.76 | — | — | |
| SCHEMBL30977655 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698353-B1 | WASTEWATER TREATMENT USING MICROBIAL STRAINS | NOVOZYMES BIOLOGICALS INC (US) | 2024-02-07 | — | — | EP | claimed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | claimed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2002501024-A | — | — | 2002-01-15 | — | — | JP | claimed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | claimed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | claimed |
| CN-122079899-A | Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-115586273-B | Compound non-targeting identification method based on bromine isotope labeling | 遵义医科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-116134035-B | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999046240-A2 | HALOGENATED AMIDINO AMINO ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5502065-A | TREATING HEADACHES | PFIZER INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0636129-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |